Form 8-K - Current report:
SEC Accession No. 0000950170-25-070416
Filing Date
2025-05-13
Accepted
2025-05-13 16:23:09
Documents
13
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tpst-20250513.htm   iXBRL 8-K 50851
2 EX-99.1 tpst-ex99_1.htm EX-99.1 178149
3 GRAPHIC img73128808_0.jpg GRAPHIC 24232
  Complete submission text file 0000950170-25-070416.txt   419026

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tpst-20250513.xsd EX-101.SCH 45225
15 EXTRACTED XBRL INSTANCE DOCUMENT tpst-20250513_htm.xml XML 6246
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 25940506
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)